Pharma shares in focus; Dr Reddys, Aurobindo, Glenmark hit record highs

Elder Pharma, TTK Healthcare, Suven Life, Aarti Drugs, Fortis Healthcare and Vivimed Lab were up 2%-8%.

SI Reporter Mumbai
Last Updated : Jul 14 2015 | 11:29 AM IST
Shares of pharmaceutical companies are in focus, with frontline drug makers such as Dr Reddy’s Laboratories, Aurobindo Pharma, Glenmark Pharmaceuticals, Alembic Pharma and Fortis Healthcare touching lifetime highs today.

At 1031 hours, the CNX Pharma index was up 0.52% or 67 points at 12,764, compared to a marginal 0.03% decline in the CNX Nifty.

Dr Reddy’s Laboratories is up 1.5% at Rs 3,813 after hitting a record high of Rs 3,785 on the BSE in intra-day trades. The company announced post market hours on Monday that it has launched Memantine hydrochloride tablets of 5 mg and 10 mg. The product is a therapeutic equivalent generic version of Namenda of Forest Laboratories LLC, a wholly owned subsidiary of Dublin-headquartered global pharmaceutical company Actavis PLC.

Namenda tablets brand had US sales of approximately $1.4 billion for the recent twelve months ending in May 2015, Dr Reddy's said quoting the IMS Health data. The drug is indicated for the treatment of moderate to severe dementia of Alzheimer's.

Aurobindo Pharma was up 1% at Rs 1,510, extending its previous day’s 3% gain on the BSE, after the company received final approval from the US Food and Drug Administration (UFDA) to produce and sell Flecainide Acetate Tablets -- used for regulating heart rate -- in the American market.

Other pharma stocks such as Elder Pharma, TTK Healthcare, Suven Life Sciences, Fortis Healthcare, Vivimed Laboratories, Aarti Drugs, Marksans Pharma and Claris Lifesciences were also up 2%-8% in an otherwise subdued market.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 14 2015 | 10:58 AM IST

Next Story